Fresenius Kabi in talks with Akorn for takeover

Entry into a formal agreement with respect to a transaction remains subject to, among other things, approval by the executive board and supervisory board of Fresenius Management SE and the board of directors of Akorn.

There can be no assurance any transaction will result from these discussions, or as to the terms of any such transaction. Neither Fresenius nor Akorn intend to make any additional comments regarding these negotiations unless and until it is appropriate to do so, or a formal agreement has been reached.

Akorn Inc is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. Akorn has manufacturing facilities located in Decatur (Illinois); Somerset (New Jersey); Amityville (New York); Hettlingen (Switzerland) and Paonta Sahib (India) that manufacture ophthalmic, injectable and specialty sterile and non-sterile pharmaceuticals.

Fresenius Kabi is a global health care company that specialises in medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients.